Voyager Therapeutics, Inc.
VYGR
$3.24
-$0.16-4.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.46M | 36.49M | 40.37M | 31.32M | 42.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.46M | 36.49M | 40.37M | 31.32M | 42.58M |
| Cost of Revenue | 116.06M | 125.35M | 132.27M | 134.31M | 128.68M |
| Gross Profit | -81.60M | -88.86M | -91.90M | -102.99M | -86.10M |
| SG&A Expenses | 32.09M | 35.07M | 36.44M | 37.22M | 37.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 148.15M | 160.42M | 168.72M | 171.53M | 165.98M |
| Operating Income | -113.69M | -123.92M | -128.34M | -140.21M | -123.40M |
| Income Before Tax | -107.60M | -116.52M | -119.58M | -126.06M | -107.26M |
| Income Tax Expenses | 126.00K | 121.00K | 144.00K | 719.00K | 679.00K |
| Earnings from Continuing Operations | -107.73 | -116.64 | -119.72 | -126.78 | -107.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.73M | -116.64M | -119.72M | -126.78M | -107.93M |
| EBIT | -113.69M | -123.92M | -128.34M | -140.21M | -123.40M |
| EBITDA | -109.87M | -119.94M | -124.28M | -136.19M | -119.18M |
| EPS Basic | -1.81 | -1.98 | -2.04 | -2.17 | -1.85 |
| Normalized Basic EPS | -1.09 | -1.20 | -1.24 | -1.35 | -1.15 |
| EPS Diluted | -1.82 | -1.98 | -2.05 | -2.17 | -1.86 |
| Normalized Diluted EPS | -1.09 | -1.20 | -1.24 | -1.35 | -1.15 |
| Average Basic Shares Outstanding | 237.78M | 235.90M | 234.76M | 233.79M | 232.84M |
| Average Diluted Shares Outstanding | 237.78M | 235.90M | 234.76M | 233.79M | 232.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |